52364-31-5Relevant academic research and scientific papers
Synthesis of Rovafovir Etalafenamide (Part III): Evolution of the Synthetic Process to the Phosphonamidate Fragment
Ambrosi, Andrea,Bringley, Dustin A.,Calimsiz, Selcuk,Curl, Jonah,Garber, Jeffrey A. O.,Huynh, Huy,Kwong, Bernard,Lapina, Olga,Leung, Edmund,Lin, Lennie,Martins, Andrew,McGinitie, Teague,Mohan, Sankar,Phull, Jaspal,Roberts, Ben,Rosario, Mary,Sarma, Keshab,Shen, Jinyu,Shi, Bing,Standley, Eric A.,Wang, Li,Wang, Xueqing,Yu, Guojun
, p. 1247 - 1262 (2021/05/29)
Phosphonamidate 1 is a key fragment in the assembly of rovafovir etalafenamide, a novel nucleotide reverse transcriptase inhibitor under development at Gilead Sciences for the treatment of HIV infection. An early manufacturing route, relying on simulated moving bed (SMB) chromatography for the separation of phosphorus diastereomers, was executed on scale to produce multiple batches of 1. However, developing alternative synthetic conditions became desirable in consideration of the high production cost, long lead time, and high process mass intensity (PMI) associated with SMB. Several strategies to improve these factors are described herein, including epimerization and recycling of the undesired (R)-phosphorus diastereomer, design of stereoselective approaches to establish the desired (S)-configuration at phosphorus, and identification of conditions or derivatives to allow for selective crystallization. Ultimately, a second-generation route to 1 was developed and demonstrated on scale. The new route achieves the separation of phosphorus diastereomers by means of selective crystallization, does not require SMB, and offers lower PMI, cost, and lead time.
Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148
Mackman, Richard L.,Ray, Adrian S.,Hui, Hon C.,Zhang, Lijun,Birkus, Gabriel,Boojamra, Constantine G.,Desai, Manoj C.,Douglas, Janet L.,Gao, Ying,Grant, Deborah,Laflamme, Genevieve,Lin, Kuei-Ying,Markevitch, David Y.,Mishra, Ruchika,McDermott, Martin,Pakdaman, Rowchanak,Petrakovsky, Oleg V.,Vela, Jennifer E.,Cihlar, Tomas
experimental part, p. 3606 - 3617 (2010/08/05)
GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosph onic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively
Phosphorus-containing phenolic, thiophenolic or aminophenyl flame-retardant hardener, and epoxy resins cured thereby
-
, (2008/06/13)
A hardener for an epoxy resin comprises a phenolic, thiophenolic, aminophenyl, tris-phenolic, tris-thiophenolic, tris-aminophenyl, tetrakis-phenolic, tetrakis-thiophenolic, or tetrakis-aminophenyl compounds; or phenol-formaldehyde or phenol-formaldehyde/melamine-formaldehyde resins wherein the phenyl rings are substituted with at least one of the structures wherein R1and R2independently are H, C1-C18alkyl, C6-C18aryl, C6-C18substituted aryl, C6-C18aryl methylene, or C6-C18substituted aryl methylene; X is O, S or NH and Ar is wherein R is C1-C4alkyl and n=0-5.
(Phosphonomethyl)trifluoromethyl sulfonates
-
, (2008/06/13)
The compound (phosphonomethyl)perfluoroalkyl sulfonate can be represented by the formula STR1 wherein n is from 0 to 7 and R and R1 are independently selected from the group consisting of hydrogen, 2-cyanoethyl, monovalent hydrocarbons containing from 1 to 18 carbons, monovalent hydrocarbonoxyhydrocarbons containing from 1 to 18 carbons, halogenated monovalent hydrocarbons containing from 1 to 18 carbons and from 1 to 3 halogens, halogenated monovalent hydrocarbonoxyhydrocarbons containing from 1 to 18 carbons and from 1 to 3 halogens. The compound is useful as an intermediate to prepare amino-phosphorous compounds such as N-phosphonomethylglycine.
